Navigation Links
For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
Date:4/30/2013

BURLINGTON, Mass., April 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European infectious disease specialists agree that effect on recurrence rate is one of the drug attributes that most influences their prescribing decisions when treating Clostridium difficile infections (CDIs). Similarly, surveyed hospital pharmacy directors indicate a high willingness to grant favorable formulary status to therapies that can demonstrate a decrease in recurrence rates of CDIs. However, even though clinical data and interviewed key opinion leaders indicate that emerging therapies provide a significant advantage over current standard-of-care therapies, marketers will need to be cognizant of price in a CDI market dominated by inexpensive and efficacious alternatives.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Market Opportunity Awaits Therapies That Provide Low Rates of CDI Recurrences finds that surveyed U.S. infectious disease specialists would prescribe Cubist's surotomycin to 15 percent of their CDI patients, driven mostly by surotomycin's lower rate of CDI recurrence relative to oral vancomycin (ViroPharma's Vancocin; generics). However, Decision Resources forecasts that surotomycin will earn a more-modest patient share of 5 percent, constrained partially by continued uptake of fidaxomicin (Optimer/Cubist's Dificid; Astellas' Dificlir), which has already demonstrated superiority in recurrence rates over oral vancomycin.

"Uptake of surotomycin will likely be constrained, unless it can demonstrate either higher clinical efficacy than Dificid or offer more favorable pricing", said Decision Resources Analyst Maria Ascano Ph.D. "Other factors that will also limit surotomycin's uptake are competition from other emerging therapies like cadazolid (Actelion) and MK-3415A (Merck), generic entry of oral vancomycin capsules, and the continued use of oral preparations of IV vancomycin."

Nevertheless, surveyed hospital pharmacy directors are highly willing to grant favorable formulary inclusion to therapies that provide increased clinical cure rates, particularly in CDI patients that suffer from severe and/or recurrent infections. As a result, market opportunity awaits therapies that can demonstrate higher overall clinical efficacy in patients with difficult-to-treat CDIs.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
3. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
4. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
5. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
6. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
7. The Growing Cost of Aging: Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
8. The Nairobi Hospital in Kenya Commences Treating Cancer with Advanced Radiotherapy Delivery Using Varian Equipment and Software
9. Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
10. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
11. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Affairs leaders at pharmaceutical organizations are looking to either start or ... some companies have conducted a significant number of clinical trials in ... as India and China ... India are now requiring local clinical trials to win ... China and India are ...
(Date:2/12/2016)... , Feb. 12, 2016  Innophos Holdings, Inc. (NASDAQ: ... specialty ingredients, today announced that it will host a live ... ET to discuss its fourth quarter and full year 2015 ... The press release detailing fourth quarter and full year results ... close. --> --> ...
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
Breaking Medicine Technology:
(Date:2/13/2016)... Springs, FL (PRWEB) , ... February 13, 2016 , ... ... the environmental impact of American businesses. , The increasingly modern world of instantaneous ... more often on non-renewable energy sources such as oil and coal, which pollutes our ...
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and ... J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA ... Southern Nevada Healthcare System. This will be the first Fisher House in Nevada, ...
Breaking Medicine News(10 mins):